What is myxofibrosarcoma?
Myxofibrosarcoma is a soft-tissue cancer that grows from fibroblasts, the cells that make the connective tissue holding the body together. It is one of the most common sarcomas in older adults.
The name describes what the tumour is made of. “Myxo” refers to a soft, jelly-like (myxoid) material, and “fibro” refers to the fibrous cells within it.
It usually appears as a painless lump in the arm or leg, often just under the skin. Many people first think it is a harmless fatty lump or a cyst.
Myxofibrosarcoma has an unusual way of growing. It sends thin, finger-like extensions along the layers of tissue (fascia) beyond the main lump. This makes it easy to leave tumour behind at surgery, and it is the main reason the cancer often comes back in the same place.
Tumours range from low grade (slow-growing, rarely spreading) to high grade (more likely to spread to the lungs). The main treatment is wide surgery with radiotherapy, carried out at a specialist sarcoma centre.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Soft-tissue sarcoma of fibroblastic origin |
| How common | One of the commonest sarcomas in people over 50; about 5-10% of adult soft-tissue sarcomas |
| Typical age | Mostly 50-80; rare under 20 |
| Sex | Slightly more common in men |
| Main sites | Arms and legs, especially the thigh; about two-thirds lie just under the skin |
| Key feature | Infiltrative growth along fascia, giving a high risk of local recurrence |
| Spread | Lungs and, less often, bone and lymph nodes; mainly in high-grade tumours |
| Main treatments | Wide surgery, radiotherapy, chemotherapy for advanced disease |
| Outlook | About 60-75% alive at 5 years; better for low-grade tumours |
2. Grades of myxofibrosarcoma
| Grade | Microscope features | Behaviour |
|---|---|---|
| Low grade | Mostly jelly-like tissue with few, mildly abnormal cells and fine curved blood vessels | Grows slowly; often comes back locally but rarely spreads |
| Intermediate grade | More cells and more abnormal nuclei | Higher risk of recurrence and some risk of spread |
| High grade | Solid areas of very abnormal cells, many cell divisions and dead tissue (necrosis) | Spreads in about a quarter to a third of cases, mostly to the lungs |
A low-grade tumour that comes back can return at a higher grade. This is one reason why getting the first operation right matters so much.
Myxofibrosarcoma used to be called “myxoid malignant fibrous histiocytoma“. Today the high-grade form is closely related to undifferentiated pleomorphic sarcoma.
3. Causes and risk factors
The cause is not known. Myxofibrosarcoma is not inherited, and no lifestyle factor has been shown to cause it.
| Factor | Notes |
|---|---|
| Age | Risk rises with age; most people are over 60 |
| Genetic changes in the tumour | Complex changes in many chromosomes, with frequent loss of tumour-suppressor genes such as CDKN2A, TP53 and NF1; there is no single gene fusion |
| Previous radiotherapy | Rarely, a sarcoma develops years after radiotherapy to the same area |
| Injury | Not a cause, though an injury may make someone notice an existing lump |
4. How does it look?
4.1 On the body
| Feature | What it looks or feels like |
|---|---|
| Lump | A soft or rubbery, painless lump, often 3-10 cm, in the thigh, knee area, arm or shoulder |
| Depth | Most are just under the skin, so the lump is easy to feel and may look like a bulge |
| Shape | Several connected lumps (multinodular), with poorly defined edges |
| Skin | Usually normal; very large tumours may stretch the skin |
| Growth | Gradual, over months; sometimes faster in high-grade tumours |
| After surgery | A new lump in or near the scar is the usual sign of recurrence |
4.2 On scans
| Test | Typical findings |
|---|---|
| Ultrasound | A lobulated, partly cystic-looking mass under the skin |
| MRI | The key test. Jelly-like areas are very bright on T2 images. A thin “tail sign” of tumour spreading along the fascia is typical and helps the surgeon plan the margins |
| CT chest | Looks for spread to the lungs |
| PET-CT | Sometimes used for high-grade tumours |
4.3 Under the microscope
| Feature | What the pathologist sees |
|---|---|
| Background | Pale, jelly-like (myxoid) material |
| Blood vessels | Fine, curved (curvilinear) blood vessels, with tumour cells clustered around them |
| Cells | Spindle-shaped cells with enlarged, dark, irregular nuclei; more abnormal in higher grades |
| Pseudolipoblasts | Cells with bubbly cytoplasm that can look like fat cells |
| Stains | No specific marker; tests are mainly used to rule out other tumours, such as myxoid liposarcoma (which has a DDIT3 fusion) |
5. Symptoms
The main symptom is a lump. Pain is uncommon until the tumour is large.
5.1 Common symptoms
| Symptom | Notes |
|---|---|
| Painless lump | The most common sign, usually in a limb, especially the thigh |
| Slow growth | The lump gets bigger over weeks or months |
| Aching | When the lump presses on muscle, nerves or a joint |
| Heaviness or tightness | With large tumours |
| Lump in a scar | After previous removal of a “benign” lump |
5.2 Symptoms of advanced disease
| Area | Possible symptoms |
|---|---|
| Lungs | Cough, breathlessness, chest pain; small spots often cause no symptoms |
| Bone | Bone pain |
| General | Tiredness, loss of appetite, weight loss |
5.3 When to see a doctor
See a doctor if you have a lump that is:
- Larger than about 5 cm, roughly the size of a golf ball
- Growing, even slowly
- Deep under the muscle layer or fixed in place
- Painful
- Back again after it was removed
Lumps under the skin are very common and nearly always harmless. A lump with any of these features should be scanned before anyone removes it, so that a sarcoma is not cut out without proper planning.
Conditions that can look similar
Several harmless and malignant lumps can look like myxofibrosarcoma on a scan or under the microscope.
| Condition | How it differs |
|---|---|
| Lipoma | A soft, fatty lump; looks like fat on MRI and does not have a myxoid tail |
| Ganglion or cyst | Fluid-filled, usually next to a joint or tendon |
| Intramuscular myxoma | A benign jelly-like tumour inside a muscle, with very few cells and a GNAS mutation |
| Nodular fasciitis | A fast-growing but harmless reaction that often settles on its own; carries a USP6 rearrangement |
| Myxoid liposarcoma | Younger adults, deep thigh; has a FUS::DDIT3 or EWSR1::DDIT3 fusion |
| Low-grade fibromyxoid sarcoma | Younger adults; has a FUS::CREB3L2 fusion and MUC4 staining |
6. Diagnosis
| Test | Why it is done |
|---|---|
| Examination and history | Size, depth, growth and how long the lump has been present |
| Ultrasound | First test for many lumps |
| MRI with contrast | Maps the tumour and its tail along the fascia |
| Core needle biopsy | Confirms the diagnosis and grade; the track is placed so it can be removed with the tumour |
| Expert pathology review | Myxoid tumours are tricky to classify; review by a sarcoma pathologist is recommended |
| CT chest | Checks for lung spread before treatment |
Staging
The TNM system for soft-tissue sarcoma of the limbs and trunk is used. It combines tumour size, lymph node spread, distant spread and the FNCLCC grade. Tools such as Sarculator can estimate the individual risk of recurrence and death after surgery.
7. Treatment
Treatment should be planned by a multidisciplinary sarcoma team, including a sarcoma surgeon, plastic surgeon, radiation oncologist, medical oncologist, radiologist and pathologist. Studies show fewer recurrences when the first operation is done at a specialist centre.
Because many patients are older, the team also takes into account general health, mobility and personal wishes. Treatment can usually be adapted, for example by using shorter radiotherapy courses.
7.1 Localised disease
| Treatment | What it involves | Notes |
|---|---|---|
| Wide excision | Removal of the tumour with a cuff of healthy tissue, including the tail seen on MRI | The cornerstone of treatment; done by a sarcoma surgeon |
| Reconstruction | Skin grafts or tissue flaps to close the wound | Often needed because wide margins leave a large defect |
| Radiotherapy | Usually about 50 Gy before surgery, or 60-66 Gy after | Recommended for intermediate- and high-grade tumours, and for many deep or large low-grade ones; lowers local recurrence |
| Re-excision | A second operation | When a lump was removed without planning and margins are unclear |
| Chemotherapy before or after surgery | Doxorubicin and ifosfamide | Considered only for selected large, deep, high-grade tumours in fit patients |
7.2 Recurrent or advanced disease
| Option | Notes |
|---|---|
| Further surgery | For a local recurrence, often with radiotherapy if not given before |
| Removal of lung spots | For a few lung metastases appearing after a long gap |
| Doxorubicin | The standard first chemotherapy for metastatic sarcoma |
| Other drugs | Gemcitabine with docetaxel, trabectedin, eribulin or pazopanib in later lines |
| Radiotherapy | To control pain or a troublesome site |
| Clinical trials | Including immunotherapy, to which some myxofibrosarcomas respond |
8. Side effects of treatment
| Treatment | Possible effects | What helps |
|---|---|---|
| Surgery | Wound infection, slow healing, weakness or stiffness | Physiotherapy, wound care |
| Radiotherapy before surgery | Higher risk of wound complications | Careful surgical planning, plastic surgery input |
| Radiotherapy after surgery | Later stiffness, fibrosis, swelling and joint problems | Stretching, lymphoedema care |
| Chemotherapy | Hair loss, nausea, infections, tiredness, heart effects with doxorubicin | Supportive medicines, heart monitoring |
9. Outlook
| Situation | What to expect |
|---|---|
| Low grade, removed with clear margins | Excellent survival; local recurrence is the main concern |
| Intermediate or high grade | Spread to the lungs in about 20-35% |
| Local recurrence | Common overall, in about a quarter to a half of cases depending on margins; can be treated again |
| Metastatic disease | Usually not curable; treatment aims to control the disease and symptoms |
| Overall | About 60-75% alive 5 years after diagnosis |
The main factors are grade, size, depth and the quality of the surgical margins. Older age and other health problems also influence treatment choices and results.
10. Follow-up
| Time after treatment | Typical follow-up |
|---|---|
| Years 1-3 | Examination and MRI of the treated area, with chest imaging, every 3-4 months for high-grade tumours |
| Years 4-5 | Every 6 months |
| After 5 years | Yearly; local recurrence can occur late |
Low-grade tumours may be followed less often for the chest but still need regular checks of the treated area. Tell your team if you notice a new lump in or near the scar.
Recovery after limb surgery takes time. A physiotherapist can help rebuild strength and movement, and an occupational therapist can suggest aids at home. Keep the treated skin moisturised and protected from the sun, and ask about compression garments if the limb swells.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Why did it come back after my first operation? | Myxofibrosarcoma spreads microscopically along tissue layers, beyond what can be felt or seen, so wide margins and radiotherapy are needed |
| Is it inherited? | No. It is not passed on in families |
| Can I keep my limb? | Almost always. Limb-sparing surgery with radiotherapy is standard |
| Will I need chemotherapy? | Not usually for localised disease; it is mainly used if the cancer spreads |
| Can I exercise after treatment? | Yes. Gradual exercise and physiotherapy help recovery |
12. Questions to ask your care team
- What grade is my tumour, and how big and deep is it?
- Was the MRI reviewed for a tail sign, and how wide will the margins be?
- Do I need radiotherapy, and will it be before or after surgery?
- Will I need a skin graft or flap to close the wound?
- What is my personal risk of recurrence or spread?
- How often will I have scans, and who should I call if I notice a new lump?
Resources
- WHO Classification of Tumours Editorial Board (2020) Soft Tissue and Bone Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
- Mentzel, T. et al. (1996) ‘Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant’, American Journal of Surgical Pathology, 20(4), pp. 391-405.
- Sanfilippo, R. et al. (2011) ‘Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution’, Annals of Surgical Oncology, 18(3), pp. 720-725.
- Haglund, K.E. et al. (2012) ‘Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma’, International Journal of Radiation Oncology, Biology, Physics, 82(1), pp. 361-367.
- Roland, C.L. et al. (2016) ‘Myxofibrosarcoma’, Surgical Oncology Clinics of North America, 25(4), pp. 775-788.
- Radaelli, S. et al. (2022) ‘Treatment strategies and outcomes of primary myxofibrosarcomas in a large patients cohort’, European Journal of Surgical Oncology, 48(8), pp. 1723-1729.
- Gronchi, A. et al. (2021) ‘Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(11), pp. 1348-1365.
- National Cancer Institute (2026) Adult Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.